Washington Post Is Confused: Pharmaceutical Industry Lobbyists Try to Increase Profits, not Improve Global Health

March 15, 2014

The Washington Post finds politics to be very confusing. It apparently thinks that the people paid high six or even seven figure salaries to lobby for the pharmaceutical industry are humanitarians trying to advance global health. 

Toward the end of an article on efforts by drug companies to get stronger patent-type protections in the Trans-Pacific Partnership (TPP) the Post told readers:

“But pharmaceutical industry advocates worry that without strong global rules, the drug development process will suffer.”

Of course the industry advocates say they “worry” that drug development will suffer, just as the defense lawyer always says her client is innocent. Just as lawyers are paid to defend their clients, lobbyists are paid to promote the case for their client. Newspaper reporters and editors should understand this fact.

It would also be worth mentioning that the protections being pushed by the pharmaceutical industry in this deal will likely worsen inequality and lead to fewer jobs for workers in the United States. They will transfer more money to the shareholders and top executives of the drug companies. They will also leave consumers in the countries who are parties to the TPP with less money to buy U.S. made products.

Comments

Support Cepr

APOYAR A CEPR

If you value CEPR's work, support us by making a financial contribution.

Si valora el trabajo de CEPR, apóyenos haciendo una contribución financiera.

Donate Apóyanos

Keep up with our latest news